Preliminary findings on the variation of serum apolipoprotein levels in neural degenerative disorders

Abstract

We measured six apolipoproteins (AI, AII, B, CII, CIII, and E) in the serum of patients with several kinds of neural diseases [diabetic neuropathy and neural degenerative disorders (motor neuron degenerative disorders, spinocerebellar degeneration, Parkinson's disease)], comparing them to the age-matched healthy controls using the immunoturbidimetric method. Statistically significant decreases of serum apo-AI, apo-A-II and increases of apo-CIII, apo-E were observed in neural degenerative diseases; and, particularly, higher apo-B and apo-CII concentrations were observed in diabetic neuropathy. Most neural degenerative disease showed lower apo-AII. However, in motor neuron degenerative disorders, higher apo C-II and apo-E were seen. Lower apo-AI was seen in spinocerebellar degeneration, and lower apo-AII was seen in Parkinson's disease. Higher apo-B, CII, and E levels were observed in females with spinocerebellar degeneration and Parkinson's disease, and lower apo-AII was seen in males with spinocerebellar disease.

Increased Levels of Apolipoprotein D in Cerebrospinal Fluid and Hippocampus of Alzheimer's Patients

“…Although the differences were less significant than those observed for apoD, apoE levels were also significantly higher in the CSF of AD patients (p < 0.001) and in patients with other neuropathologies (p < 0.05) than in the CSF of control subjects. In other studies, apoE concentrations in the CSF of AD subjects have been reported to be higher (Carlsson et al, 1991;Ikeda et al, 1993), comparable (Pirttila et al, 1994), or lower (Blennow et al, 1994;Lehtimaki et al, 1995) than those of control subjects. Increased CSF apoE levels have been reported in several other neuropathologies, including Creutzfeld-Jakob disease (Namba et al, 1991;Amouyel et al, 1994), scrapie disease (Diedrich et al, 1991), and Lewy body disease (St.-Clair et al, 1994).…”

Are Blood-Based Protein Biomarkers for Alzheimer's Disease also Involved in Other Brain Disorders? A Systematic Review

“…A number of proteins did not show clear directions in their associations with the various conditions with the results of different studies contradicting each other. For example, apolipoprotein E was found to be elevated in PD by Ikeda et al [65], but lowered in Alberio et al [52] and Goldknopf et al [56]. This could be due to small sample sizes, cohort heterogeneity and differences in proteomic approaches, and will need further validation.…”

“…(−) Alberio et al [52] (−) Dean et al [51] (−) Soares et al [18] (−) Goldknopf et al [56] (−) Doecke et al [17] (+) Ikeda et al [65] (−) Hu et al [19] (−) Zhang et al [21] With Brain Amyloid: (−) Kiddle et al [20] (+) Thambisetty et al [27] With treatment response: (+) Akuffo et al [23] Alpha-2-macroglobulin (+) Schwarz et al [58] (+) Fujita et al [49] (+) Akuffo et al [23] (−) Domenici et al [60] (+) Tsiouris et al [50] With AD:…”

Quantitative proteomic analysis of serum proteins in patients with Parkinson’s disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry

“…It is recognized that some apolipoproteins are involved in the process, such as Apo AI, Apo A-II, Apo E. There was evidence found in the literature that significant decreases of serum Apo A-I, Apo A-II and increases of Apo C-III, Apo E were discovered in neural degenerative diseases. 4 There are a large portion of amphipathic a-helices in the protein structure domain of Apolipoproteins. This can maintain the conformational stability without lipid proteins to form the amyloid-like protein deposition, such as aand b-synuclein which also have amphipathic a-helix domains.…”